{"id":19619,"date":"2022-11-08T17:37:03","date_gmt":"2022-11-08T12:07:03","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=19619"},"modified":"2023-01-05T09:54:58","modified_gmt":"2023-01-05T04:24:58","slug":"pharma-news-for-amgen-sanofi-anavex","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-sanofi-anavex","title":{"rendered":"Amgen\u2019s Olpasiran Candidate; GSK\u2019s Novel Antibiotic for Urinary Tract Infections; AstraZeneca and Sanofi\u2019s Beyfortus Approval; FDA Orphan Designation to Anavex\u2019s Anavex2-73; FDA Rare Pediatric Disease Designation to Sensorion\u2019s OTOF-GT; GSK\u2019s Blenrep Fails in Phase III Trial in R\/R Multiple Myeloma"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d73fba3002d\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d73fba3002d\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-sanofi-anavex\/#Amgen_Reports_Promising_Mid-stage_Results_for_its_Olpasiran_Candidate\" >Amgen Reports Promising Mid-stage Results for its Olpasiran Candidate&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-sanofi-anavex\/#AstraZeneca_and_Sanofi_Secures_Approval_in_the_EU_for_Beyfortus\" >AstraZeneca and Sanofi Secures Approval in the EU for Beyfortus<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-sanofi-anavex\/#GSKs_Blenrep_Fails_in_Phase_III_Trial_in_Relapsed_or_Refractory_Multiple_Myeloma\" >GSK\u2019s Blenrep Fails in Phase III Trial in Relapsed or Refractory Multiple Myeloma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-sanofi-anavex\/#GSK_Preps_Filing_for_Novel_Antibiotic_for_Urinary_Tract_Infections\" >GSK Preps Filing for Novel Antibiotic for Urinary Tract Infections<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-sanofi-anavex\/#Anavex_Gets_FDA_Orphan_Designation_for_Anavex2-73_in_Fragile_X_Syndrome\" >Anavex Gets FDA Orphan Designation for Anavex2-73 in Fragile X Syndrome<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-sanofi-anavex\/#Sensorion_Announces_US_FDA_Grants_Rare_Pediatric_Disease_Designation_to_its_OTOF-GT\" >Sensorion Announces US FDA Grants Rare Pediatric Disease Designation to its OTOF-GT<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-amgen-reports-promising-mid-stage-results-for-its-olpasiran-candidate\"><span class=\"ez-toc-section\" id=\"Amgen_Reports_Promising_Mid-stage_Results_for_its_Olpasiran_Candidate\"><\/span><strong>Amgen Reports Promising Mid-stage Results for its Olpasiran Candidate&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Amgen <\/strong>has reported encouraging mid-stage results for its <strong>olpasiran <\/strong>candidate for lowering lipoprotein(a) &#8211; a risk factor for atherosclerotic cardiovascular disease &#8211; and now plans to move forward with a phase III program as soon as possible. The <strong>OCEAN(a)-DOSE<\/strong> trial\u2019s final results, published in the New England Journal of Medicine, showed that the siRNA drug reduced Lp(a) levels compared to placebo at all four doses tested, with doses above <strong>75 mg<\/strong> given every 12 weeks cutting levels by <strong>95%<\/strong> or more after six months.<\/p>\n\n\n\n<p>Amgen still needs to demonstrate that the reduction in Lp(a) is associated with lower rates of cardiovascular outcomes, and it will do so in its phase III program, which will begin enrolling a target of <strong>6,000<\/strong> patients later this year.<\/p>\n\n\n\n<p>The company released top-line data from the study earlier this year but did not share detailed findings. It is lagging behind a rival Lp(a) targeting an antisense drug called <strong>pelacarsen <\/strong>from <strong>Novartis <\/strong>and development partner <strong>Akcea<\/strong>, which is already in a phase III trial called <strong>HORIZON <\/strong>with major cardiovascular events (MACE) as its primary endpoint.<\/p>\n\n\n\n<p><strong>Novartis <\/strong>exercised a <strong>USD 150 million<\/strong> option on the drug in 2019 after phase II results with once-weekly dosing of <strong>20mg pelacarsen<\/strong> showed that <strong>98%<\/strong> of patients achieved a reduction in Lp(a) levels that brought them below the <strong>50mg\/dL<\/strong> threshold considered to be a risk. Amgen\u2019s less frequent dosing may work in its favor, but the sheer size of the potential market means that if both drugs are approved, there will be plenty of room in the market for both.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"AstraZeneca_and_Sanofi_Secures_Approval_in_the_EU_for_Beyfortus\"><\/span><strong>AstraZeneca and Sanofi Secures Approval in the EU for Beyfortus<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Beyfortus<\/strong>, the first single-dose drug to protect newborns and infants from respiratory syncytial virus (RSV) infections developed by <strong>AstraZeneca <\/strong>and <strong>Sanofi<\/strong>, has been approved in the EU. According to the two pharmaceutical companies, the antibody-based drug has been cleared by the European Commission with a broad label, covering both full-term and pre-term babies, as well as those with various health conditions that could make them vulnerable to RSV. It is the first time <strong>Beyfortus (nirsevimab)<\/strong> has been approved by a regulatory body.<\/p>\n\n\n\n<p><strong>Synagis (palivizumab)<\/strong> from <strong>AstraZeneca <\/strong>is currently the only approved drug in Europe for passive RSV prophylaxis, but it must be administered monthly, whereas <strong>nirsevimab <\/strong>can provide protection for the entire RSV season with a single injection. <strong>Sobi <\/strong>sells it in the United States.<\/p>\n\n\n\n<p><strong>Beyfortus <\/strong>reduced the incidence of medically attended lower respiratory tract infections (LRTI) caused by RSV by <strong>74.5% <\/strong>compared to placebo in the <strong>MELODY trial<\/strong>, and it was at least as effective as Synagis in protecting pre-term infants, those with chronic lung disease (CLD), or those with congenital heart disease (CHD) from the virus in the <strong>MEDLEY study<\/strong>. The new drug will be available before <a href=\"https:\/\/www.delveinsight.com\/report-store\/respiratory-syncytial-virus-rsv-pipeline-insight\">RSV vaccines<\/a>, which are intended to protect newborns in the months following birth by vaccinating expectant mothers who pass on antibodies against the virus in the womb.<\/p>\n\n\n\n<p><strong>Synagis<\/strong>, a former blockbuster that was approved in 1998, is still selling well despite losing patent protection, with AstraZeneca earning <strong>USD 410 million<\/strong> from the drug last year. However, revenue from the antibody is expected to plummet once Beyfortus and RSV vaccines hit the <a href=\"https:\/\/www.delveinsight.com\/report-store\/respiratory-syncytial-virus-rsv-market\">RSV market<\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"GSKs_Blenrep_Fails_in_Phase_III_Trial_in_Relapsed_or_Refractory_Multiple_Myeloma\"><\/span><strong>GSK\u2019s Blenrep Fails in Phase III Trial in Relapsed or Refractory Multiple Myeloma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>GSK<\/strong> has high hopes for <strong>Blenrep<\/strong>, its BCMA-directed cancer drug, but a failed phase III trial in relapsed or refractory multiple myeloma has cast doubt on its prospects \u2013 and even the status of its regulatory approval. The <a href=\"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-pipeline\">antibody-drug conjugate (ADC)<\/a> <strong>Blenrep (belantamab mafodotin)<\/strong> failed to improve on standard pomalidomide\/dexamethasone therapy in patients who had previously received at least two rounds of lenalidomide and proteasome inhibitor therapy in the <strong>DREAMM-3 trial.<\/strong><\/p>\n\n\n\n<p>The median progression-free survival (PFS) for <strong>Blenrep <\/strong>was around 11 months versus seven months, but this was not a statistically significant difference, as was the overall response rate (ORR) at <strong>41% and 36%<\/strong>, and overall survival at <strong>21.2 months<\/strong> and <strong>21.1 months<\/strong>, respectively.<\/p>\n\n\n\n<p>While the FDA granted Blenrep accelerated approval for patients with multiple myeloma who had received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent, <strong>DREAMM-3<\/strong> was designed as a confirmatory trial. That means Blenrep technically hasn\u2019t met the criteria for staying on the market, and its approval for 2020 is in jeopardy. And in recent years, the FDA has become much stricter when it comes to meeting post-marketing requirements for drugs with accelerated approvals.<\/p>\n\n\n\n<p>Needless to say, <strong>GSK\u2019s <\/strong>chances of moving <strong>Blenrep <\/strong>up the treatment pathway into earlier-line use have plummeted, as have its hopes of making Blenrep a <strong>\u00a33 billion<\/strong> blockbuster. Despite being the first drug targeting BCMA to reach the <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-myeloma-market\">relapsed or refractory multiple myeloma market<\/a>, <strong>GSK <\/strong>reported a <strong>\u00a336 million<\/strong> profit in the third quarter.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"GSK_Preps_Filing_for_Novel_Antibiotic_for_Urinary_Tract_Infections\"><\/span><strong>GSK Preps Filing for Novel Antibiotic for Urinary Tract Infections<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On 03 November 2022, the <strong>GSK <\/strong>announced that the pivotal <strong>phase III EAGLE-2<\/strong> and <strong>EAGLE-3 trials<\/strong> evaluating <strong>gepotidacin<\/strong>, an <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/uncomplicated-urinary-tract-infections-pipeline-insight\" class=\"ek-link\">investigational treatment for Uncomplicated Urinary Tract Infection (uUTI)<\/a><\/strong> in female adults and adolescents, will stop enrolment early for efficacy following a recommendation by the <strong>Independent Data Monitoring Committee (IDMC)<\/strong>. This decision was based on a prespecified interim analysis of efficacy and safety data in over <strong>3000 patients<\/strong> across the trials.\u00a0<\/p>\n\n\n\n<p>As per the updates by GSK, the EAGLE-2 and EAGLE-3 trials met the primary efficacy endpoint of combined clinical and microbiological resolution following treatment at the <strong>Test-Of-Cure (TOC)<\/strong> visit for gepotidacin versus nitrofurantoin in <a href=\"https:\/\/www.delveinsight.com\/report-store\/uncomplicated-urinary-tract-infection-epidemiology-forecast\" class=\"ek-link\"><strong>patients with a confirmed uUTI<\/strong><\/a> and a uropathogen sensitive to nitrofurantoin. The IDMC review did not identify any safety concerns.<\/p>\n\n\n\n<p>GSK\u2019s Gepotidacin is a novel, investigational bactericidal, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by a distinct mechanism of action and equally and independently binds to two different Type II topoisomerase enzymes. GSK has further updates; the EAGLE-2 and 3 trials are now closed for recruitment, with final study visits and data collection anticipated during the first quarter of 2023. GSK is looking further to work with regulatory authorities to commence regulatory filings for gepotidacin in <strong>H1 2023.<\/strong> Moreover, full trial results will also be submitted for presentation at a scientific congress and for publication in a peer-reviewed journal in <strong>2023<\/strong>.<\/p>\n\n\n\n<p>As per DelveInsight, the uUTIs is one of the most common infections in the community, and about <strong>150 million UTIs<\/strong> occur yearly worldwide. The <a href=\"https:\/\/www.delveinsight.com\/report-store\/uncomplicated-urinary-tract-infection-epidemiology-forecast\" class=\"ek-link\"><strong>annual incidence of Uncomplicated Urinary Tract Infection<\/strong><\/a> (or acute cystitis) in women is <strong>12%<\/strong>. In the US, there are over <strong>1 million catheter-associated UTIs\/year<\/strong>, and up to <strong>40%<\/strong> of hospital gram-negative bacteremia\/year originate as UTIs.\u00a0\u00a0<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Anavex_Gets_FDA_Orphan_Designation_for_Anavex2-73_in_Fragile_X_Syndrome\"><\/span><strong>Anavex Gets FDA Orphan Designation for Anavex2-73 in Fragile X Syndrome<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On 8 November 2022,<strong> Anavex Life Sciences<\/strong> announced that the US FDA had granted <strong>Orphan Drug Designation (ODD)<\/strong> to <strong>ANAVEX\u00ae2-73 (blarcamesine)<\/strong> for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/fragile-x-syndrome-fxs-market\"><strong>treatment of Fragile X syndrome<\/strong><\/a>. <strong>Christopher U Missling<\/strong>, Ph.D., President and Chief Executive Officer of Anavex, has said, \u201cWe look forward to working with the Fragile X syndrome community to rapidly advance ANAVEX\u00ae2-73 as a potential treatment for Fragile X syndrome while we continue to expand the late-stage clinical investigation of ANAVEX\u00ae2-73 as part of its precision medicine platform technology for both neurodevelopmental and neurodegenerative indications.\u201d<\/p>\n\n\n\n<p>Apart from Fragile X Syndrome, Anavex Life Sciences is working on other product portfolio platforms, which includes its drug lead candidate <strong>ANAVEX\u00ae2-73<\/strong> for the treatment of <strong>Alzheimer\u2019s disease, Parkinson\u2019s disease dementia, Parkinson\u2019s disease <\/strong>&amp; <strong>Rett syndrome<\/strong> and <strong>ANAVEX\u00ae3-71<\/strong> for <strong>schizophrenia<\/strong>, <strong>frontotemporal dementia, and Alzheimer\u2019s disease.<\/strong><\/p>\n\n\n\n<p>Fragile X syndrome (FXS) is the most common form of inherited intellectual disability disorder affecting about <strong>1 in 4,000 males<\/strong> and <strong>1 in 6,000 females<\/strong>. Worldwide, an estimated <strong>1,088,500 people<\/strong> are estimated to be affected by FXS. As per DelveInsight, in 2021, the total <a href=\"https:\/\/www.delveinsight.com\/report-store\/fragile-x-syndrome-fxs-epidemiology-forecast\"><strong>diagnosed prevalent population of Fragile X Syndrome<\/strong><\/a> in the 7MM was estimated to be around <strong>120,900<\/strong> in 2021. Similarly, in the US, there were around 69,798 diagnosed prevalent populations of FXS.&nbsp;<\/p>\n\n\n\n<p>Currently,&nbsp; there is no approved <a href=\"https:\/\/www.delveinsight.com\/report-store\/fragile-x-syndrome-pipeline-insight\"><strong>treatment for Fragile X syndrome<\/strong><\/a>. The approval and launch of the <strong>Anavex2-73<\/strong> in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/fragile-x-syndrome-fxs-market\"><strong>Fragile X Syndrome therapeutics market<\/strong><\/a> is expected to immensely improve the treatment landscape in the coming years.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Sensorion_Announces_US_FDA_Grants_Rare_Pediatric_Disease_Designation_to_its_OTOF-GT\"><\/span><strong>Sensorion Announces US FDA Grants Rare Pediatric Disease Designation to its OTOF-GT<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On November 07, 2022, <strong>Sensorion <\/strong>announced that the <strong>US FDA<\/strong> had granted <strong>Rare Pediatric Disease Designation<\/strong> to its therapeutics candidate, <strong>OTOF-GT<\/strong>, a gene therapy intended to <a href=\"https:\/\/www.delveinsight.com\/report-store\/hearing-loss-pipeline-insight\"><strong>treat otoferlin gene-mediated hearing loss<\/strong><\/a>.<\/p>\n\n\n\n<p>Sensorion\u2019s is working on the <strong>OTOF-GT gene therapy<\/strong> development program that aims to restore hearing in people living with otoferlin deficiency. The otoferlin protein is large and is delivered to the inner ear using two standard <a href=\"https:\/\/www.delveinsight.com\/report-store\/adeno-associated-virus-vectors-in-gene-therapy-market\"><strong>gene therapy vectors (AAV)<\/strong><\/a><strong> <\/strong>and assembled in place. Earlier, in September 2022, Sensorion received a positive opinion on an application for <strong>Orphan Drug Designation (ODD)<\/strong> from the <strong>European Medicines Agency (EMA)<\/strong>.<\/p>\n\n\n\n<p>Patients with OTOF mutations suffer from severe to profound <a href=\"https:\/\/www.delveinsight.com\/report-store\/sudden-sensorineural-hearing-loss-ssnhl-market\"><strong>sensorineural prelingual non-syndromic hearing loss<\/strong><\/a>. Sensorion has progressed with preclinical and clinical development plans for OTOF-GT and is on track to file a <strong>Clinical Trial Application (CTA)<\/strong> in the first half of <strong>2023<\/strong>. The designation is another key piece in the puzzle that helps advance Sensorion towards clinical development in OTOF-GT in <strong>2023<\/strong>.\u201d<br>Otoferlin deficiency is one of the most common forms of congenital deafness.&nbsp; Currently, there are no approved therapies for Otoferlin deficiency. It is responsible for about <strong>8%<\/strong> of all cases of congenital hearing loss. In the United States and Europe, about <strong>20,000 people<\/strong> are affected by the Otoferlin deficiency. The positive approach and acknowledgment by the FDA and ongoing clinical development activities and research in the <strong>Otoferlin deficiency therapeutics market<\/strong> by major pharma giants such as Sensorion and others are expected to provide a better treatment outcome in the coming years for the affected population with this debilitating conditions.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Amgen Reports Promising Mid-stage Results for its Olpasiran Candidate&nbsp; Amgen has reported encouraging mid-stage results for its olpasiran candidate for lowering lipoprotein(a) &#8211; a risk factor for atherosclerotic cardiovascular disease &#8211; and now plans to move forward with a phase III program as soon as possible. The OCEAN(a)-DOSE trial\u2019s final results, published in the New [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":19628,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":6,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[77,750,19908,17006,19909,349,410,19906,420,639,17615,19907,18792,937],"industry":[17225],"therapeutic_areas":[17238,17230,17233,17231,17228,17236,17234],"class_list":["post-19619","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-antibody-drug-conjugate","tag-fragile-x-syndrome","tag-fragile-x-syndrome-treatment","tag-hearing-loss","tag-hearing-loss-treatment","tag-latest-pharma-news","tag-multiple-myeloma","tag-multiple-myeloma-treatment","tag-news","tag-pharma-news","tag-respiratory-syncytial-virus","tag-uncomplicated-urinary-tract-infection","tag-uncomplicated-urinary-tract-infections-market","tag-urinary-tract-infections","industry-pharmaceutical","therapeutic_areas-genetic-disorders","therapeutic_areas-genito-urinary-system-and-sex-hormones","therapeutic_areas-hematological-disorders","therapeutic_areas-infectious-diseases","therapeutic_areas-oncology","therapeutic_areas-otolaryngology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News Updates | Amgen, Sanofi, Anavex, Sensorion, GSK, AZs<\/title>\n<meta name=\"description\" content=\"Amgen\u2019s Olpasiran; AstraZeneca and Sanofi\u2019s Beyfortus Approval; Anavex\u2019s Anavex2-73; Sensorion\u2019s OTOF-GT; GSK\u2019s Blenrep; GSK\u2019s gepotidacin\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-sanofi-anavex\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News Updates | Amgen, Sanofi, Anavex, Sensorion, GSK, AZs\" \/>\n<meta property=\"og:description\" content=\"Amgen\u2019s Olpasiran; AstraZeneca and Sanofi\u2019s Beyfortus Approval; Anavex\u2019s Anavex2-73; Sensorion\u2019s OTOF-GT; GSK\u2019s Blenrep; GSK\u2019s gepotidacin\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-sanofi-anavex\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-08T12:07:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-01-05T04:24:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/08173630\/Pharma-News-for-Amgen-AstraZeneca-Sanofi-Anavex-Sensorion-GSK.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News Updates | Amgen, Sanofi, Anavex, Sensorion, GSK, AZs","description":"Amgen\u2019s Olpasiran; AstraZeneca and Sanofi\u2019s Beyfortus Approval; Anavex\u2019s Anavex2-73; Sensorion\u2019s OTOF-GT; GSK\u2019s Blenrep; GSK\u2019s gepotidacin","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-sanofi-anavex","og_locale":"en_US","og_type":"article","og_title":"Pharma News Updates | Amgen, Sanofi, Anavex, Sensorion, GSK, AZs","og_description":"Amgen\u2019s Olpasiran; AstraZeneca and Sanofi\u2019s Beyfortus Approval; Anavex\u2019s Anavex2-73; Sensorion\u2019s OTOF-GT; GSK\u2019s Blenrep; GSK\u2019s gepotidacin","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-sanofi-anavex","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-11-08T12:07:03+00:00","article_modified_time":"2023-01-05T04:24:58+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/08173630\/Pharma-News-for-Amgen-AstraZeneca-Sanofi-Anavex-Sensorion-GSK.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-sanofi-anavex","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-sanofi-anavex","name":"Pharma News Updates | Amgen, Sanofi, Anavex, Sensorion, GSK, AZs","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-sanofi-anavex#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-sanofi-anavex#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/08173630\/Pharma-News-for-Amgen-AstraZeneca-Sanofi-Anavex-Sensorion-GSK.png","datePublished":"2022-11-08T12:07:03+00:00","dateModified":"2023-01-05T04:24:58+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Amgen\u2019s Olpasiran; AstraZeneca and Sanofi\u2019s Beyfortus Approval; Anavex\u2019s Anavex2-73; Sensorion\u2019s OTOF-GT; GSK\u2019s Blenrep; GSK\u2019s gepotidacin","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-sanofi-anavex"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-amgen-sanofi-anavex#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/08173630\/Pharma-News-for-Amgen-AstraZeneca-Sanofi-Anavex-Sensorion-GSK.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/08173630\/Pharma-News-for-Amgen-AstraZeneca-Sanofi-Anavex-Sensorion-GSK.png","width":772,"height":482,"caption":"Pharma News for Amgen, AstraZeneca, Sanofi, Anavex, Sensorion, GSK"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/08173630\/Pharma-News-for-Amgen-AstraZeneca-Sanofi-Anavex-Sensorion-GSK-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Antibody-Drug Conjugate<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Fragile X syndrome<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Fragile X Syndrome Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Hearing Loss<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Hearing Loss Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Multiple Myeloma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Multiple Myeloma Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Respiratory Syncytial Virus<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Uncomplicated Urinary Tract Infection<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Uncomplicated Urinary Tract Infections Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Urinary Tract Infections<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Antibody-Drug Conjugate<\/span>","<span class=\"advgb-post-tax-term\">Fragile X syndrome<\/span>","<span class=\"advgb-post-tax-term\">Fragile X Syndrome Treatment<\/span>","<span class=\"advgb-post-tax-term\">Hearing Loss<\/span>","<span class=\"advgb-post-tax-term\">Hearing Loss Treatment<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma Treatment<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Respiratory Syncytial Virus<\/span>","<span class=\"advgb-post-tax-term\">Uncomplicated Urinary Tract Infection<\/span>","<span class=\"advgb-post-tax-term\">Uncomplicated Urinary Tract Infections Market<\/span>","<span class=\"advgb-post-tax-term\">Urinary Tract Infections<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Nov 8, 2022","modified":"Updated on Jan 5, 2023"},"absolute_dates_time":{"created":"Posted on Nov 8, 2022 5:37 pm","modified":"Updated on Jan 5, 2023 9:54 am"},"featured_img_caption":"Pharma News for Amgen, AstraZeneca, Sanofi, Anavex, Sensorion, GSK","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/19619","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=19619"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/19619\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/19628"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=19619"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=19619"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=19619"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=19619"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=19619"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}